Pediatrix Medical Group (MD) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Speaker0 Certain statements and information during this conference call may be deemed to be forward looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward looking statements are based on assumptions and assessments made by Pediatrics' management in light of their experience and assessment of historical trends, current conditions, expected future developments, and other fa ...

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this physician group would post earnings of $0.37 per share when it actually produced earnings of $0.51, delivering a surprise of 37.84%.Over the last four quarters, t ...

Financial Performance - Net revenue for the three months ended March 31, 2025, was $458.4 million, a decrease of $36.7 million, or 7.4%, compared to $495.1 million for the same period in 2024[73] - Same-unit net revenue increased by $26.1 million, or 6.2%, driven by a $19.4 million increase from net reimbursement-related factors and a $6.7 million increase related to patient service volumes[73] - Adjusted EBITDA for the three months ended March 31, 2025, was $49.2 million, compared to $37.2 million for the same period in 2024, reflecting an increase of $11.9 million[72] - Adjusted EPS for the three months ended March 31, 2025, was $0.33, compared to $0.20 for the same period in 2024, representing a 65% increase[72] - Income from operations increased by $16.2 million, or 102.0%, to $32.1 million for the three months ended March 31, 2025, compared to $15.9 million for the same period in 2024[79] - Operating margin improved to 8.4% for the three months ended March 31, 2025, up from 4.9% for the same period in 2024[80] - Net income rose to $20.7 million for the three months ended March 31, 2025, compared to $4.0 million for the same period in 2024[83] - Adjusted EBITDA increased to $49.2 million for the three months ended March 31, 2025, from $37.2 million for the same period in 2024[83] Expenses - Practice salaries and benefits decreased by $32.1 million, or 8.7%, to $337.0 million for the three months ended March 31, 2025, compared to $369.1 million for the same period in 2024[74] - General and administrative expenses were $58.6 million for the three months ended March 31, 2025, a decrease of $1.6 million compared to $60.2 million for the same period in 2024[76] - Transformational and restructuring related expenses were $6.6 million for the three months ended March 31, 2025, compared to $8.5 million for the same period in 2024[78] - Total non-operating expenses decreased to $4.0 million for the three months ended March 31, 2025, from $8.1 million for the same period in 2024[81] Cash Flow and Liquidity - Cash used in operating activities decreased to $116.1 million for the three months ended March 31, 2025, from $122.6 million for the same period in 2024[87] - As of March 31, 2025, the company had $99.0 million in cash and cash equivalents, down from $229.9 million at December 31, 2024[85] - The outstanding principal balance on the Amended Credit Agreement was $210.9 million as of March 31, 2025[96] - A 1% change in interest rates would impact income before taxes by approximately $2.1 million per year based on the outstanding balance of the Amended Credit Agreement[104] Operational Metrics - The percentage of patient service revenue reimbursed under government-sponsored healthcare programs decreased during the three months ended March 31, 2025, compared to the same period in 2024[61] - Days sales outstanding (DSO) improved to 47.6 days at March 31, 2025, down from 52.2 days at March 31, 2024[89] Strategic Changes - The company completed the exit of its pediatric office-based practices as of December 31, 2024, to focus on hospital-based and maternal-fetal medicine services[62] - The company anticipates potential impacts from changes in government-sponsored healthcare programs and the expiration of COVID-19 related emergency declarations[67]

• Net revenue of $458 million; • Net income of $21 million; and • Adjusted EBITDA of $49 million. Operating Results– Three Months Ended March 31, 2025 Pediatrix's net revenue for the three months ended March 31, 2025 was $458.4 million, compared to $495.1 million for the prior-year period. This decrease reflects the impact of non-same unit activity, primarily practice dispositions, partially offset by growth in same-unit net revenue of 6.2 percent. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice Pres ...

Physician services provider Pediatrix Medical Group, Inc. (MD) is set to report its first-quarter 2025 results on May 6, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 25 cents per share and $454.5 million, respectively. (See the Zacks Earnings Calendar to stay ahead of market-making news.)The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year- ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

Figure 1 Midland Announces the Acquisition of the Kan Gold Project Figure 2 Midland Announces the Acquisition of the Kan Gold Project Figure 3 Midland Announces the Acquisition of the Kan Gold Project Figure 4 Midland Announces the Acquisition of the Kan Gold Project Figure 5 Midland Announces the Acquisition of the Kan Gold Project Figure 6 Midland Announces the Acquisition of the Kan Gold Project Figure 7 Midland Announces the Acquisition of the Kan Gold Project Figure 8 <img ...

Figure 1 Midland Increases its Copper Land Position in the Labrador Trough Figure 2 Midland Increases its Copper Land Position in the Labrador Trough MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to report that 167 mining claims with strong copper potential were designated in the central part of the Labrador Trough, Quebec (new “Kuiper” project; Figures 1A and 1B), following the identification of several highly favourable parameters for copp ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Core Viewpoint - Pediatrix Medical Group (MD) shows potential for upside with a mean price target of $18.21, indicating a 28% increase from the current trading price of $14.23 [1] Price Target Analysis - The mean estimate consists of seven short-term price targets with a standard deviation of $1.35, suggesting variability in analyst predictions [2] - The lowest estimate of $17 indicates a 19.5% increase, while the highest estimate suggests a 47.6% surge to $21 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [7] Earnings Estimates - Analysts have shown increasing optimism about MD's earnings prospects, with a strong consensus in revising EPS estimates higher [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 6.1%, with five estimates moving higher and one lower [10] - MD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Analyst Behavior - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated expectations [6] - Despite the skepticism surrounding price targets, the direction implied by them can serve as a useful guide for potential price movements [12]